Dr. Abigail S. Chan, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 109
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 54059 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uofl Health - Jewish Hospital and Mary & Elizabeth Hospital Louisville, KY
- University of Louisville Hospital Louisville, KY
Medical groups
- University of Louisville Physicians Inc (1,445 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 109
- Services billed
- 350
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 45 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Louisville, KY | 69 |
| Dexamethasone Other prescribers in Louisville, KY | 68 |
| Ondansetron Hcl Other prescribers in Louisville, KY | 53 |
| Prochlorperazine Maleate Other prescribers in Louisville, KY | 48 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Louisville, KY | 38 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Louisville, KY | 26 |
| Eliquis (apixaban) Other prescribers in Louisville, KY | 24 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Louisville, KY | 20 |
| Pantoprazole Sodium Other prescribers in Louisville, KY | 18 |
| Gabapentin Other prescribers in Louisville, KY | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 45 payments worth $1,096 in total to this clinician.
| Daiichi Sankyo Inc. | $147 |
|---|---|
| Terumo Medical Corporation | $146 |
| Astellas Pharma US Inc | $139 |
| Novartis Pharmaceuticals Corporation | $122 |
| Celgene Corporation | $104 |
| E.r. Squibb & Sons, L.l.c. | $99.97 |
| Merck Sharp & Dohme LLC | $52.55 |
| Takeda Pharmaceuticals U.S.A., Inc. | $45.19 |
| Food and Beverage | $1,071 |
|---|---|
| Education | $25.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Oct 7, 2025 | Education BRAFTOVI · ONCOLOGY · in-kind | $25.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $41,499 in research payments for these studies, mostly to the institutions running them.
- CHS38802
Coherus Oncology, Inc. - A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinom…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.